TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06005597

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monotherapy obicetrapib
Description: tablet; 10mg obicetrapib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy ezetimibe
Description: capsule; 10mg ezetimibe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination Therapy placebo
Description: tablet; no active ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Therapy placebo
Description: tablet; no active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Combination Therapy placebo
Description: tablet; no active ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obicetrapib Placebo
Description: tablet; no active ingredient
Study: NCT06708429

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)
Study: NCT06567262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM metallic removable partial denture
Description: Make digital scans using an intraoral scanning device. Scan the maxillary (antagonistic scan) and mandibular (pre-preparation scan) arches, as well as an initial digital record of the inter-occlusal relation (occlusal scan).~Analyse the digital cast using CAD software. Primary electronic surveying will be carried out to ensure if the tooth preparations will be needed.~Make a definitive intraoral scan only of the prepared teeth and record the maxillary-mandibular relationship.~The virtual cast is digitally surveyed and the design of the framework is done using computer software. The wax pattern 3D framework information will be converted into a standard tessellation language (STL) file and transfer to a rapid prototyping (RP) system to be printed and finally cast using the conventional technique to produce RPD framework.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional metallic removable partial denture
Description: Primary impressions will be taken, the impressions will be poured to construct a study casts.~Maxillary Face-bow record and diagnostic bite will be taken. The study casts will be mounted on semi adjustable articulator to check inter-arch space.~Surveying of the study cast will be done. Required mouth preparation will be carried out then secondary impression will be taken using special tray.~Secondary impression will be poured to obtain master cast which will be surveyed to confirm proper mouth preparation, blocked out and then wax pattern will be designed and constructed.~A metallic framework will be obtained using the conventional lost wax technique and casting.~Intraoral try in of the framework will be done followed by bite registration record.~The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally.
Study: NCT05644132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InDx Implant for the carpometacarpal joint
Description: Treatment of thumb base joint arthritis with the InDx Implant
Study: NCT06039761

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digestive or gynecological surgery by laparoscopy
Description: Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digestive or gynecological surgery by laparoscopy
Description: Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
Study: NCT06005597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib Placebo
Description: tablet; no active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Obicetrapib Placebo
Description: tablet; no active ingredient
Study: NCT06708429

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)
Study: NCT06679569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg/hr continuous infusion
Description: To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.
Study: NCT06679244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure technique
Description: This is an innovative surgical method applied in proximal gastrectomy. By adding anti reflux structures such as false gastric fundus and false cardia on the basis of esophageal residual gastric anastomosis, the goal of anti reflux is achieved, while maintaining normal physiological channels and fully utilizing residual gastric function, reducing the difficulty of proximal gastrectomy surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Totally laparoscopic proximal gastrectomy with double-tract reconstruction
Description: This is a traditional surgical method that has been widely used in proximal gastrectomy. After disconnecting the proximal stomach, performing Roux-en-Y anastomosis of the esophagus and jejunum firstly, followed by lateral anastomosis of the residual stomach and jejunum. Previous studies have confirmed its safety and effectiveness, but there are also issues of gastric channel disuse and high missed detection rate of residual stomach.
Study: NCT06679192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Milled thickness varied soft upper surface, based on plantar pressure measurement
Description: This custom made shoe insole is milled, with a thickness varied soft upper surface ranging from 0-6mm in thickness. The base of the insole is 45 shore Ethylene-vinyl acetate (EVA).~This intervention makes the insole from an individual foot scan, a plantar pressure measurement from the individual and the shoe model to mill a finished custom made shoe insole with a soft upper surface. It is difficult in clinical practice of making shoe inserts to create a thickness varied soft upper with different zones all over the insole. Furthermore, a soft upper requires a physical positive model to be made of the foot and staff must spend time to grind the insole to an acceptable shape. A milled version would be more effective since it require no physical foot model, little to no work grinding the insole and enables the use of thickness-variations. It also enables the use of data-based insole-manufacturing, such as data from plantar pressure measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3mm soft upper surface
Description: This intervention has a 3mm soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No soft upper surface
Description: This intervention has a no soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
Study: NCT05212038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iliopsoas plane block group
Description: Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham block group
Description: Ultrasound-guided iliopsoas plane block with normal saline 10 ml
Study: NCT05793632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
Study: NCT05491850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Physical Activity for Peripheral Diabetic Neuropathy
Description: Moderate physical activity can increase movement and heart rate are particularly important for people suffering with peripheral neuropathy. Physical activity can improve blood circulation, which strengthens nerve tissues by increasing the flow of oxygen.
Study: NCT04954989

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU
Description: Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU
Description: Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU
Description: Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU
Description: Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously
Study: NCT05881291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1.
Study: NCT06428357

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Bovine Lactoferrin
Description: Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recombinant Bovine Lactoferrin
Description: Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Bovine Lactoferrin
Description: Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
Study: NCT06005597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ezetimibe Placebo
Description: capsule; no active ingredient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ezetimibe Placebo
Description: capsule; no active ingredient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe Placebo
Description: capsule; no active ingredient
Study: NCT05693766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg taken by mouth twice daily for 7 days on, 7 days off

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine-therapy
Description: Endocrine therapy administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MammoPrint ® and BluePrint assays
Description: Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MammoPrint ® and BluePrint assays
Description: Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
Study: NCT05226598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
Study: NCT05086770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin microsphere (Nexsphere™)
Description: Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
Study: NCT05226598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
Study: NCT05281276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
Study: NCT06428357

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Bovine Lactoferrin
Description: Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bovine Milk-Derived Lactoferrin
Description: Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
Study: NCT06010706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised physical therapy manual exercise program.
Description: 1. Mobilization Techniques :~   The joint mobilization technique will be the anterior-posterior glide of the talus. The participant will be positioned in supine or long sitting.~2. Stretching Exercise:~   Passive stretching with therapist assistance was used for ankle dorsiflexion with the knee both flexed and extended. Force during passive stretching was modified to patient tolerance. Each participant flexed the knee slightly while standing on a 10° incline board. The participant was asked to slightly flex both knees until a stretch was felt in the calf muscle.~3. Strengthening Exercise:~The resistance training protocol will be based on the progressive resistance training principle and was a modification of the protocol used by Frontera et al \[10\] in older men. Plantar-flexion resistance training will be performed on a customized hydraulic apparatus, which provide a constant resistance over the entire ROM and allow for concentric as well as eccentric.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise, ROM, Strengthening exercises.
Description: Patients at the control group will receive instruction for home based exercise program of physical therapy exercise. The home program primarily consisted of exercises targeting deficits in joint ROM, muscle flexibility and strength, and balance.
Study: NCT05625061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) Intervention
Description: All participants receive a mobile behavioral weight loss intervention delivered through a study smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback, and daily weight-related behavioral goals; a connected physical activity tracker and wireless scale. As micro-randomized trials are sequential, full factorial experiments, this core intervention component is combined with each of the 7 intervention messages (i.e., Behavior Change Technique (BCT) messages) to be tested repeatedly over time.~Participants will be evaluated at each of 3 decision points (morning, midday, evening) on each day of the study, and if eligible then micro-randomized, to receive or not receive, 1 of 7 types of daily intervention messages promoting achievement of proximal weight-related behavioral goals.
Study: NCT06428357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Milk-Derived Lactoferrin
Description: Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
Study: NCT05625061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique 1 Message (Action Planning)
Description: Core BWL Intervention + Message in smartphone app prompts detailed planning of performance of one of the 3 target behaviors (daily weighing, active minutes, red food intake).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique 2 Message (Discrepancy between Current Behavior and Goal)
Description: Core BWL Intervention + Message in smartphone app provides feedback on each of the 3 target behaviors (daily weighing, active minutes, red food intake) in the form of information drawing attention to discrepancies between participants' current behavior and participants' daily goals.
Study: NCT05281276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
Study: NCT05625061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique 3 Message (Feedback on Outcome of Behavior)
Description: Core BWL Intervention + Message in smartphone app provides participants with feedback on their weight change, relating it to their performance on one of the 3 target behaviors (daily weighing, active minutes, red food intake).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique 4 Message (Social Support)
Description: Core BWL Intervention + Message in smartphone app advises participants on eliciting the provision of social support from their existing network related to one of the 3 target behaviors (daily weighing, active minutes, red food intake).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique 5 Message (Social Comparison)
Description: Core BWL Intervention + Message in smartphone app systematically induces comparison of participants' behavioral performance with other participants, including general, upward (i.e., comparison to participants doing better: weighing more, engaging in more activity, staying within red food limits), and downward comparisons (to participants doing worse).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique 6 Message (Social Reward)
Description: Core BWL Intervention + Message in smartphone app reinforces participants' effort or progress in performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Technique 7 Message (Focus on Past Success)
Description: Core BWL Intervention + Message in smartphone app advises participants to think about or list previous successes related to performing one of the 3 target behaviors (daily weighing, active minutes, red food intake).
Study: NCT06428357

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will take a single dose equal to 3 capsules daily before a meal for 4 weeks. Meal timing is not controlled.
Study: NCT03066739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 0.1 micrograms/kg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil+ Placebo
Description: high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil +ultra-low dose naloxone
Description: high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
Study: NCT05335434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THOR LX2.3 with LED Lollipop
Description: The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
Study: NCT05580406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach messaging
Description: Participants will receive outreach messages via health care system secure messaging and/or phone following a new diagnosis of depression made in primary care if the participant has failed to initiate treatment (pharmacotherapy or psychotherapy) within 30 days of new diagnosis.